Cara Therapeutics reported $22.33M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 266.96M 37.53M
Acelrx Pharmaceuticals ACRX:US $ 26.33M 8.04M
Aerie Pharmaceuticals AERI:US $ 79.96M 42.74M
Antares Pharma ATRS:US $ 45.13M 10.53M
Arena Pharmaceuticals ARNA:US $ 514.18M 81.2M
Biodelivery Sciences International BDSI:US 119.85M 3.42M
Cara Therapeutics CARA:US $ 22.33M 184K
Chugai Pharma 4519:JP Y 192518M 5387M
Depomed DEPO:US $ 54.43M 6.6M
Endo International Ordinary Shares ENDP:US $ 1545.17M 117.4M
Halozyme Therapeutics HALO:US $ 446.97M 52.48M
Horizon Pharma HZNP:US $ 812.32M 0.71M
Neurocrine Biosciences NBIX:US $ 368M 15.4M
Pacira Pharmaceuticals PCRX:US $ 105.77M 39.08M
Pain Therapeutics PTIE:US $ 278.25M 3.94M
Redhill Biopharma RDHL:US $ 51.82M 24.16M
Revance Therapeutics RVNC:US $ 167.63M 81.79M
Supernus Pharmaceuticals SUPN:US $ 223.77M 31.87M
Teva Pharmaceutical Industries TEVA:US $ 2436M 693M
Vanda Pharmaceuticals VNDA:US $ 57.24M 14.89M